Global Female Hypoactive Sexual Desire Disorder Therapeutics Market Size By Type (BP-101, Bremelanotide, Gepirone Hydrochloride ER, PVT-011), By Application (Out-Patient, In-Patient), By Geographic Scope And Forecast

Female Hypoactive Sexual Desire Disorder Therapeutics Market Size And Forecast

Female Hypoactive Sexual Desire Disorder Therapeutics Market size is valued at USD 1.85 Billion in the year 2021 and it is expected to reach USD 3.64 Billion in 2030, growing at a CAGR of 7.76% from 2023 to 2030.

The increasing incidence of Female Hypoactive Sexual Desire Disorder, increased awareness of available treatments, and increasing demand for effective and safe therapies all contribute to market growth. The Global Female Hypoactive Sexual Desire Disorder Therapeutics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Female Hypoactive Sexual Desire Disorder Therapeutics Market Definition

Disorder of Female Hypoactive Sexual Desire Therapeutics refers to the application of treatments for female hypoactive sexual desire disorder. Female Hypoactive Sexual Desire Disorder Therapeutics are important because they can help enhance the quality of life for women who suffer from this condition. The DSM-IV-TR defines hypoactive sexual desire disorder (HSDD) as a persistent or recurring absence of sexual fantasies and desires for sexual activity that causes significant personal distress or interpersonal difficulties.

The symptoms are not better explained by another axis I diagnosis and are not caused by the direct physiological effects of a drug or medical condition. It is further subdivided into lifelong or acquired, generalized or situational. The International Society for the Study of Women’s Sexual Health defined HSDD as either an absence of motivation for sexual activity or a lack of interest to get involved or engage in sexual activity that must be accompanied by clinically significant personal distress and must last at least 6 months.

Global Female Hypoactive Sexual Desire Disorder Therapeutics Market Overview

Advances in pharmaceutical research and development have resulted in the launch of targeted medications specifically designed for Female HSDD, providing patients with more treatment options. Female HSDD is increasingly being recognized as a legitimate medical condition, with regulatory agencies approving medications to treat it, fueling the market growth. However, treatment options are limited. Despite advancements, there are still a limited number of approved treatment options for Female HSDD on the market, leading to unmet needs and challenges in effectively addressing the condition.

Along with a lack of knowledge and diagnosis, a lack of awareness and underdiagnoses between healthcare professionals and patients impedes the condition’s recognition and management. There are numerous treatment processes that are extremely expensive. This type of disorder also necessitates counseling sessions, which necessitate monthly visits at a high cost. Numerous hormonal therapies, which are somewhat necessary for a quick recovery but become costly for many patients due to their high cost, hinder the market growth.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Female Hypoactive Sexual Desire Disorder Therapeutics Market. We cover the major impacting factors driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. Porter’s five forces model can be used to assess the competitive landscape in the Global Female Hypoactive Sexual Desire Disorder Therapeutics Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

Global Female Hypoactive Sexual Desire Disorder Therapeutics Market Segmentation Analysis

The Global Female Hypoactive Sexual Desire Disorder Therapeutics Market is Segmented on the Basis of Type, Application, And Geography.

Female Hypoactive Sexual Desire Disorder Therapeutics Market, By Type

• BP-101
• Bremelanotide
• Gepirone Hydrochloride ER
• PVT-011
• Others

Based on Type, the market is segmented into BP-101, Bremelanotide, Gepirone Hydrochloride ER, PVT-011, and Others. Bremelanotide is a peptide that boosts the body’s natural melanin production. It has been demonstrated to be effective in increasing sexual desire in women who have low sexual desire. The drug was approved by the US Food and Drug Administration to be used as an antidepressant, and it acquired marketing authorization for treating hypoactive sexual desire disorder (HSDD) in females in Europe, Japan, and Australia; however, it has only received approval for HSDD treatment in China to date.

Female Hypoactive Sexual Desire Disorder Therapeutics Market, By Application

• Out-Patient
• In-Patient

Based on Application, the market is segmented into Out-Patient and In-Patient. In-patient treatment accounted for the largest share. The growing number of patients suffering from Obsessive Compulsive Sexual Desire (OCS) and related disorders contribute to the demand for GWSD therapy in a variety of applications. It is estimated that around 5% to 15% of females above 18 years have some degree of hypoactive sexual desire disorder (HSDD). Thus, increasing prevalence rates are expected to fuel market growth during the forecast period.

Female Hypoactive Sexual Desire Disorder Therapeutics Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

On the basis of Geography, the global Female Hypoactive Sexual Desire Disorder Therapeutics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. In terms of revenue, North America dominated the global Female Hypoactive Sexual Desire Disorder Therapeutics market. The existence of a large number of FH diagnostics and treatment providers, an abundance of insurance coverage for various treatments, rising disease understanding, and a high prevalence rate are some of the factors contributing to its dominant market share.  Furthermore, increased R&D investments by pharmaceutical companies are anticipated to be contributing to this growth during the forecast period.

Key Players

The “Global Female Hypoactive Sexual Desire Disorder Therapeutics Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Sprout Pharmaceuticals, Inc., Palatin Technologies, Inc., AMAG Pharmaceuticals, Inc., Pfizer Inc., Shionogi & Co., Ltd., Apricus Biosciences, Inc., Emotional Brain BV, Trimel Pharmaceuticals Corporation, Bayer AG, Evestra, Inc., Sermonix Pharmaceuticals LLC, S1 Biopharma, Inc., Takeda Pharmaceutical Company Limited, BioSante Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, among others.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the players mentioned above globally.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any